Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...
Researchers have discovered a handful of new CRISPR-Cas systems that could add to the capabilities of the already transformational gene editing and DNA manipulation toolbox. Of the new recruits, one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback